Hematology

This article highlights key insights from a symposium on treatment options for patients with relapsed/refractory diffuse large B cell…

We are delighted to present the latest issue of EMJ Hematology! This issue features a review of the scientific highlights from this year’s…

Gene therapy for haemophilia A and B was discussed during several sessions at the 64th American Society of Hematology (ASH) Annual Meeting, held 10th–13th December 2022.

This article covers multiple oral and poster presentations dedicated to gene therapy as a treatment for haemophilia A and B, which took place at the International Society on Thrombosis and Haemostasis (ISTH) Congress, 9th–13th July 2022.

Welcome to our latest issue of EMJ Hematology, which brings you quality content on the latest developments in the field and a review of the European Hematology Association (EHA) 2022 Hybrid Congress, with key highlights from the event. Featured articles include a review of the social impact and quality of life for patients with β-thalassaemia, and an article on how helical tomotherapy may be used as a valid and effective treatment for compressive atelectasis due to extramedullary haematopoiesis. 

Myelodysplastic syndromes (MDS) are a rare group of blood disorders that can result in symptoms spanning from fatigue to easy bruising and bleeding. Based on a symposium that was part of the International Congress on Myelodysplastic Syndromes by the MDS Foundation, this article provides an overview of MDS.

Haemophilia is a rare, monogenic disease that occurs from a single gene mutation and can have debilitating effects on the individual. With two subtypes, this inherited condition is currently treated with lifelong coagulation factor replacement therapy but is an ideal candidate for gene therapy management…

EXPERT discussion from a satellite symposium presented at the European Hematology Association (EHA) Virtual Congress 2021 focused on myelodysplastic syndrome (MDS), a heterogeneous group of myeloid malignancies characterised by ineffective haematopoiesis, progressive bone marrow failure, and increased risk of acute myeloid leukaemia evolution.